1 ter a mean follow-up of 334 +/- 82 days, two desensitized patients (18%) received a kidney transplant

2                 We compared outcomes between desensitized patients (DSZ) and those undergoing no DSZ

3                                              Desensitized patients had decreased SPT, sIgE, basophil

4                           A subset of highly desensitized patients is at ultra-high risk for infectio

5 lants without any desensitization treatment, desensitized patients showed higher class I (99% vs. 80%

6 ant and posttransplant blood samples from 33 desensitized patients who received alemtuzumab induction